Carmustine

Bischlorethylnitrosourea Bischlorethylnitrosurea BCNU

Therapeutic Indications

Carmustine is indicated for:

Non-Hodgkin's lymphoma, Hodgkin's disease

Irrespective of gender only Adults (18 years old or older)

Carmustine is effective in secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 150-200 mg/m² once every 6 weeks

Glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma, ependymoma, brain metastases

Irrespective of gender only Adults (18 years old or older)

Carmustine is effective in brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 150-200 mg/m² once every 6 weeks

Contraindications

Active ingredient Carmustine is contraindicated in the following cases:

Severe (end-stage) renal impairment

No gender/age discrimination

Lactation

No gender/age discrimination

It is unknown whether carmustine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Carmustine is contraindicated during breast-feeding and up to seven days post-treatment.

Severe bone marrow depression

No gender/age discrimination

Bone marrow toxicity is a common and severe toxic adverse reaction of carmustine. Complete blood count should be monitored frequently for at least six weeks after a dose. In case of a decreased number of circulating platelets, leucocytes or erythrocytes either from previous chemotherapy or other cause the dose should be adjusted. Liver, kidney and lung function should be checked and monitored regularly during therapy. Repeat doses of Carmustine Obvius should not to be given more frequently than every six weeks. The bone marrow toxicity of carmustine is cumulative and therefore the dosage adjustment must be considered on the basis of nadir blood counts from prior doses.